Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun 23;7(1):4138.
doi: 10.1038/s41598-017-00816-2.

Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-Analysis

A F O Costa  1 , D L Menezes  2 , L H S Pinheiro  2 , A F Sandes  3 , M A P Nunes  4 , D P Lyra Junior  2 , D M Schimieguel  2
Affiliations
Meta-Analysis

Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-Analysis

A F O Costa et al. Sci Rep. .

Abstract

Despite technological advances, the prognosis and survival of acute myeloid leukemia (AML) adult patients remain low, compared with other hematologic malignancies. Some antigens detected by immunophenotyping may soon play a significant role in the pathophysiologic, prognostic, and overall survival (OS) rate of AML patients. Therefore, we conducted a systematic review and meta-analysis of PubMed, Scopus, Science Direct, Web of Science, and the Cochrane Library (using PRISMA guidelines). We analyzed 11 studies and 13 antigens, detected through the immunophenotyping of 639 patients. From them, twelve exhibited a negative impact with AML prognosis. The meta-analysis demonstrated a high expression of AML markers, which have been associated with a decrease in survival over 10 months (RR 2.55; IC 95%; 1.49-4.37) and over 20 months (RR 2.46; IC 95%; 1.75-3.45). Knowing that the expression of immunophenotypic markers, which are not used on a routine basis, might be able to influence disease behavior, looks promising. However, they have been associated with a poor prognosis as well as a decrease in survival. This may allow for different chemotherapeutical protocols, including future studies for new therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram for study identification. Flow chart of how the research was systematically conducted for study identification.
Figure 2
Figure 2
Forest Plot of relative risks and confidence intervals of 10-month survival. Relative risks and confidence intervals of survival at 10 months after the withdrawal of the two studies that caused the asymmetry, associated with the non-detection/detection of the immunophenotypic markers in each study and its meta-analytical measurements.
Figure 3
Figure 3
Forest Plot of relative risks and confidence intervals of 20-month survival. Relative risks and confidence intervals of survival at 20 months associated with the non-detection/detection of the immunophenotypic markers in each study and their meta-analytical measurements.
See this image and copyright information in PMC

References

    1. Terwijn M, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J. Clin. Oncol. 2013;31:3889–3897. doi: 10.1200/JCO.2012.45.9628. - DOI - PubMed
    1. Ferrara F, Schiffer Ca. Acute myeloid leukaemia in adults. Lancet. 2013;381:484–495. doi: 10.1016/S0140-6736(12)61727-9. - DOI - PubMed
    1. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch. Pathol. Lab. Med. 2011;135:44–54. - PubMed
    1. Hasan M, et al. Semi-automated and standardized cytometric procedures for multi-panel and multi-parametric whole blood immunophenotyping. Clin. Immunol. 2015;157:261–276. doi: 10.1016/j.clim.2014.12.008. - DOI - PubMed
    1. Atfy M, Eissa M, Salah HE, El Shabrawy DA. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. Med. Oncol. 2012;29:2063–2069. doi: 10.1007/s12032-011-9993-x. - DOI - PubMed